AB Science S.A.

AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling patways within cells. Co. targets diseases such as cancer, inflammatory diseases and central nervous system diseases, in both human and veterinary medecines. Co. has developed its own portfolio of molecules including masitinib, which has already been registered in Europe and the U.S.A. and is pursuing five phase 3 studies in human medecine, including studies in pancreatic cancer, GIST, metastatic melanoma, and studies in mastocytosis and severe persistent asthma.
  • TickerAB
  • ISINFR0010557264
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

AB SCIENCE sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to AB SCIENCE (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date January 4, 2019, the closing price was EUR 3.80 and its target price was estimated at EUR 2.70.

Valérie GASTALDY

Analyse court terme - AB SCIENCE SA : La reprise est une consolidation.

La tendance est baissière. La reprise est une consolidation. La baisse risque de reprendre jusqu'à 3,600 €. La tendance de fond serait remise en cause en cas de franchissement de 4,730 €.

Valérie GASTALDY

Short term view - AB SCIENCE SA : The recovery is a consolidation.

The trend is bearish. The recovery is a consolidation. The fall might resume toward €3.600. The background trend would be questioned should prices rise above €4.730.

Valérie GASTALDY

Short term view - AB SCIENCE SA : The background trend is clearly bearish.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €4.730. The next target is at €3.600, then €3.170. Passing €4.730 would question the continuation of the fall.

A director sold 308,960 shares at 17.000EUR and

A director at AB Science sold 308,960 shares at 17.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

AB SCIENCE sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to AB SCIENCE (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date January 4, 2019, the closing price was EUR 3.80 and its target price was estimated at EUR 2.70.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Etude de l'AG du 15/12/2017

La présente assemblée vise à modifier les caractéristiques de plans d'actions de prérences ("Actions B") (résolution 2) et ceux de plans passés de bons de souscription ("BCE") et de bons de souscription d'actions ("BSA") (résolution 3 et 4). Ces plans posent à la fois des problèmes de dilution (l'ensemble des plans représente une dilution de plus de 10% du capital de la société), de plafonnement (pas de plafonnement pour les dirigeants), et parfois d'alignement avec la performance. Par conséquent, nous ne pouvons approuver aucune de ces trois résolutions. La résolution propose également la no...

Jehanne Leroy

Etude de l'AG du 28/06/2017

Tout comme l’année dernière, le rapport spécial des commissaires aux comptes portant sur les conventions et engagements réglementés n'est pas disponible dans les délais, ce qui constitue un manquement non négligeable aux devoirs d'information des actionnaires. Par conséquent, nous recommandons l'opposition à la résolution 4. Par ailleurs, la société ne présente pas non plus les politiques de rémunération des dirigeants pour 2017. On notera à ce sujet qu’interrogée par Proxinvest la société n’a pas daigné nous répondre, ce qui, là encore, montre le peu de cas que la société fait de ses actionn...

Valérie GASTALDY

Analyse court terme - AB SCIENCE SA : La reprise est une consolidation.

La tendance est baissière. La reprise est une consolidation. La baisse risque de reprendre jusqu'à 3,600 €. La tendance de fond serait remise en cause en cas de franchissement de 4,730 €.

Valérie GASTALDY

Short term view - AB SCIENCE SA : The recovery is a consolidation.

The trend is bearish. The recovery is a consolidation. The fall might resume toward €3.600. The background trend would be questioned should prices rise above €4.730.

Valérie GASTALDY

Short term view - AB SCIENCE SA : The background trend is clearly bearish.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €4.730. The next target is at €3.600, then €3.170. Passing €4.730 would question the continuation of the fall.

Valérie GASTALDY

Analyse court terme - AB SCIENCE SA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le MACD est négatif, il confirme cette tendance. La reprise est une consolidation qui va buter sur 4,730 € prochainement. Le prochain objectif est à 3,600 €, puis 3,170 €. Le franchissement de 4,730 € remettrait en cause la suite de la baisse.

Valérie GASTALDY

Medium term view - AB SCIENCE SA : The bounce is gaining strength.

The background trend is clearly bearish. The bounce is gaining strength. It is too early to qualify this market action as a bullish reversal. The background trend would be questioned should prices rise above €5.59.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch